Advanced Filters
noise

Needham, Massachusetts Clinical Trials

A listing of Needham, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,285 clinical trials
J Jenna Dargie, MS

Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present

To determine whether the use of topical otic drops intra-operative and post-operative during tympanostomy tube placement reduces the rate of tympanostomy tube occlusion and post-operative otorrhea (ear drainage) during the initial 4-week post-operative period in subjects with no middle ear effusion (fluid behind the ear drum) present at the time …

6 - 10 years of age All Phase 4
D David Kaelber, MD.PHD. MPH.

Investigating Dupilumab's Effect in Asthma by Genotype

The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate …

12 years of age All Phase 4
S Site Public Contact

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.

18 years of age All Phase 1
J Janet S Orozco, BS

Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial

The aim of the proposed pilot study is to investigate patient tolerability and efficacy of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy.

18 years of age All Phase N/A
J Jacalyn Rosenblatt, MD

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of …

18 - 80 years of age All Phase 2
B Brandon Huffman, MD

ZN-c3 + Gemcitabine in Pancreatic Cancer

This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) Gemcitabine (a nucleoside metabolic inhibitor)

18 years of age All Phase 2

MCT for the Harvard/UCSF ROBIN Center

The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that underlie how radiation treats tumors but also can …

years of age All Phase N/A
B Balachundar Subramaniam, MD, MPH

Brain Health with Inner Engineering Meditation

This study will explore whether a 21-minute meditation practice called Shambhavi Mahamudra Kriya leads to changes in brain health and explore how it affects cognitive and physiological function.

20 - 65 years of age All Phase N/A
F Fei Du, PhD

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

The primary aim of this study is to investigate the effects of exogenously administered nicotinamide riboside (NR) on brain energy metabolism, oxidative stress, and cognitive function in individuals with mild cognitive impairment (MCI) and mild Alzheimer's dementia (AD).

55 - 89 years of age All Phase N/A
A Ann M Rasmusson, MD

Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

Purpose: About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but responses vary greatly across individuals and PTSD subpopulations. Neurobiological factors impacted by life experiences, stress, and genetics can affect treatment responses. These factors can alter brain capacities needed to …

18 - 55 years of age All Phase 2

Simplify language using AI